Skip to content

Melanoma — patient experience and advocacy

TL;DR — The dominant patient-reported problem in melanoma is informational, not physical: a mixed-methods systematic review of 14 studies found informational needs the most commonly reported unmet need, ahead of psychological, social and physical needs, and found needs varying by stage across the whole disease journey (Fu 2020, PMID 32342223). In localised disease the dominant burden is fear of recurrence: among 51 survivors of localised cutaneous melanoma, fear was measured with the Fear of Cancer Recurrence Inventory short form, where a score ≥13 of 36 identifies clinically significant fear (Mahama 2024, PMID 38353983). In advanced disease the dominant burden is prognostic uncertainty created by immunotherapy itself: bereaved carers described being unable to reconcile the positive discourse around long-term disease control with the unpredictability of individual response, which left them unprepared for treatment failure and end of life (Fox 2020, PMID 32338133; Fox 2019, PMID 30515757). The best-designed melanoma intervention trial to date improved quality of life, patient activation and self-examination confidence but did not significantly reduce fear of recurrence (Hansen 2025, PMID 40504479). Ethics rules for this layer are in ../literature/patient-voice/README.md.

What patients report needing

Domain Finding
Unmet needs, ranked Informational needs most commonly reported, then psychological, then social and physical, across 14 studies (10 quantitative, 3 qualitative, 1 mixed-methods) searched 2000–2019. Needs were present throughout the cancer journey and varied by stage (Fu 2020, PMID 32342223)
Qualitative synthesis Metasynthesis of 14 studies (16 papers) on the needs and experiences of people with skin cancer, updating a 2010 review that had found only two studies — the field was under-researched until recently (Bath-Hextall 2017, PMID 27775838)
Patient-authored accounts Meta-narrative study of 214 experiential accounts drawn from the personal-story sections of melanoma and cancer support websites in four countries, differentiating supportive-care needs across three periods: lead-up to diagnosis; diagnosis, treatment and recovery; and post-treatment and recurrence (Lamprell 2018, PMID 29173015)

Fear of recurrence

Study Design Finding
Mahama 2024, PMID 38353983 Qualitative and survey study, 51 participants (mean age 49.5, 67% female) recruited from an academic dermatology practice, semistructured interviews plus FCRI-SF Threshold of ≥13 of 36 identifies clinically significant fear; interviews analysed for themes of lived experience
MELACARE (Hansen 2025, PMID 40504479) Randomised controlled trial, 153 patients with surgically treated stage IA–IIA melanoma, Denmark; nurse-led sessions on skin-self-examination technique and metacognitive strategies (n = 78) vs usual care (n = 75) At 6 months, fear of recurrence lower but not statistically significant (−0.86, 95% CI −3.34 to 1.62). Significant improvements in health-related quality of life (18%, 3–32), patient activation (0.43, 0.15–0.71) and confidence in self-examination
Uveal melanoma survivors Seven-year distress trajectories (Brown 2023, PMID 36848060); prediction of 2–5-year fear of recurrence from post-treatment symptoms and functional problems (Brown 2023, PMID 34850324); a prospective study of anxiety, depression and fear of recurrence with attention to ophthalmologist/oncologist communication in France (PMID 39548476)
Views on self-examination Patients' own views about skin self-examination after treatment for localised melanoma have been studied directly (Dieng 2019, PMID 31090868)

Fear of recurrence is the melanoma-specific counterpart of the surveillance-intensity question. MELFO showed that reduced-frequency follow-up produced no worse patient-reported outcomes and >97% satisfaction in both arms (Moncrieff 2022, PMID 35866644) — so more clinic visits are not the answer to fear, and the intervention designed to address it directly did not significantly move it (PMID 40504479).

The immunotherapy-specific burden

This is the most distinctive theme in the melanoma patient-experience literature and it is a direct product of the treatment revolution.

  • Hope shaped by clinicians, then disappointment. Among 42 patients and 10 caregivers (median age 67, 68% male, 62% with melanoma), four themes emerged: the oncology team shaped hopeful expectations of immunotherapy including as a potential cure among those with melanoma; distress from prognostic uncertainty particularly affected patients with toxicity or progression; patients without long-term responses experienced overwhelming disappointment; and patients and caregivers had conflicting preferences for prognostic information (Boulanger 2025, PMID 39038253).
  • Carers cannot reconcile the discourse with the individual case. In-depth interviews with 20 bereaved carers across three Australian metropolitan melanoma centres found uncertainty dominating the experience, with shock at diagnosis after sometimes innocuous vague symptoms and an unclear prognosis arising from the interplay between an uncertain disease trajectory and ambiguous expectations of immune and targeted therapies (Fox 2019, PMID 30515757).
  • Unpreparedness for end of life. A companion study found carers struggling to reconcile the positive discourse around immune and targeted therapies with the underlying unpredictability of individual response; expectations that these therapies necessarily provide longer survival were evident, and difficulty in prognostication combined with a desire to maintain hope produced lack of preparedness for treatment failure and end of life (Fox 2020, PMID 32338133).
  • Caregiver burden. A scoping review of caregivers of melanoma and sarcoma patients screened 325 studies and included 16, cataloguing the assessment tools used and the main areas of difficulty — high stress, anxiety and caregiving burden with psychological, social and economic repercussions (Lleshi 2026, PMID 41827744).

The mechanism is specific and identifiable: the same durable-response plateau that makes melanoma the reference case for immunotherapy success (Wolchok 2025, PMID 39282897) makes individual prognosis less predictable than in the chemotherapy era, and the patient-experience literature shows that the resulting uncertainty is itself a source of harm.

Measuring what patients experience

Instrument / question Status
FACT-Melanoma Melanoma-specific quality-of-life instrument; used in the MelMarT margins trial at baseline, 3, 6 and 12 months (Moncrieff 2018, PMID 29850955). Mapped to EQ-5D utility weights (Askew 2011, PMID 21914512), shortened to reduce patient burden (PMID 22395418), and evaluated with Rasch modelling for response-scale structure (PMID 23262441)
Preference-based measures in early-stage disease Sensitivity of preference-based quality-of-life measures for economic evaluation in early-stage melanoma has been assessed directly (PMID 29188268)
PROMs in advanced skin cancer Systematic review identifying which instruments have been used and which are validated in advanced melanoma and non-melanoma skin cancer (Reinhardt 2023, PMID 36469125)
EADV position Literature review and position paper from the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma, and Non-Melanoma Skin Cancer, cataloguing the generic, dermatology-specific, cancer-specific and melanoma-specific instruments in use (Chernyshov 2019, PMID 30963614)
Trial-embedded HRQOL KEYNOTE-054 measured long-term HRQOL with EORTC QLQ-C30 every 6 months in patients alive at 108 weeks from randomisation (Bührer 2024, PMID 39146951); EORTC 18071 reported HRQOL as a secondary outcome for adjuvant ipilimumab (Coens 2017, PMID 28162999)

Financial toxicity is measurable and age-patterned. In a cross-sectional survey of 106 advanced melanoma survivors treated with immunotherapy (39% response; median 36.4 months since starting immunotherapy, range 14.2–133.9), measured with the Comprehensive Score for Financial Toxicity alongside EORTC QLQ-C30, younger patients (<65 years) reported higher financial toxicity (P < .001) than older patients, and financial toxicity correlated with quality of life (P < .001) after controlling for age (Thom 2021, PMID 33103948). Estimated costs of ipilimumab–nivolumab therapy and its adverse events in metastatic melanoma have been modelled separately (PMID 36612030).

A patient-facing critique of adjuvant therapy exists in the literature and belongs here. A review argues that adjuvant anti-PD-1 for resected stage IIB–IV melanoma is "an example of non-personalized medicine with no overall survival benefit": recurrence-free survival improves, overall survival has not, there are no predictive markers, treatment is offered to all comers on stage alone, and a year of treatment with a risk of chronic immune-related effects may negatively affect quality of life (Ochenduszko 2024, PMID 39025250). The counter-case is in adjuvant therapy; the disagreement is real and unresolved.

Genomic risk information

Semistructured interviews with 30 participants (aged 24–69, 50% female; 12 low-risk, 8 average-risk, 10 high-risk) who had received personalised melanoma genomic risk information in a pilot trial found many reporting positive responses — happiness, reassurance and new knowledge to help manage risk. Some reported short-term negative emotional reactions that dissipated over time, and most, particularly those receiving average or high-risk results, reported making positive behaviour changes to reduce risk (Fenton 2019, PMID 30580464). This is directly relevant to the risk-stratified surveillance approaches discussed in risk factors and prevention and germline predisposition.

Uveal melanoma raises the sharpest version of the same problem: prognostic genomic testing (monosomy 3, BAP1, gene-expression class) predicts metastatic risk without an intervention that changes it. How doctors communicate genomic-test results and their prognostic impact to uveal melanoma patients has been studied qualitatively (PMID 41203514).

Advocacy organisations verified in this build

Each site below was retrieved on 2026-09-01; a live page establishes current web presence and stated mission, not independent evidence of reach or quality. The full annotated directory is ../literature/patient-voice/organizations.md.

Organisation Region URL Accessed
Melanoma Research Foundation US https://www.melanoma.org/ 2026-09-01
AIM at Melanoma Foundation US / international https://aimatmelanoma.org/ 2026-09-01
Melanoma Research Alliance US https://www.curemelanoma.org/ 2026-09-01
The Skin Cancer Foundation US https://www.skincancer.org 2026-09-01
Melanoma UK UK https://www.melanomauk.org.uk 2026-09-01
Melanoma Focus UK https://www.melanomafocus.org/ 2026-09-01
Melanoma Fund UK https://www.melanoma-fund.co.uk/ 2026-09-01
Ocular Melanoma UK (formerly OcuMel UK) UK https://omuk.org/ 2026-09-01
Macmillan Cancer Support (melanoma information) UK https://www.macmillan.org.uk/cancer-information-and-support/melanoma 2026-09-01
Melanoma Institute Australia Australia https://melanoma.org.au/ 2026-09-01
Melanoma Patients Australia Australia https://www.melanomapatients.org.au/ 2026-09-01
Cancer Council Australia (melanoma information) Australia https://www.cancer.org.au/cancer-information/types-of-cancer/melanoma 2026-09-01
Melanoma Canada Canada https://www.melanomacanada.ca/ 2026-09-01
Save Your Skin Foundation Canada https://www.saveyourskin.ca/ 2026-09-01
Melanoma Patient Network Europe Europe https://www.mpneurope.org/ 2026-09-01
Euromelanoma Europe https://www.euromelanoma.eu/ 2026-09-01
Hautkrebs-Netzwerk Deutschland Germany https://www.hautkrebs-netzwerk.de/ 2026-09-01
SkinCheck Ireland https://www.skincheck.ie/ 2026-09-01

Where the patient-voice evidence is thin

  • English-language and high-income dominance. The qualitative base is drawn overwhelmingly from Australia, the UK, the US and Northern Europe. The 214-account meta-narrative study covered four countries (PMID 29173015).
  • Acral, mucosal and skin-of-colour experience is barely represented, despite worse outcomes and later presentation in exactly those groups (Brunsgaard 2023, PMID 35533771; Yan 2022, PMID 34363907).
  • Campaign evaluation exists but does not establish melanoma-outcome benefit. A 1990 hospital series observed more diagnoses, a higher proportion of thin lesions and fewer thick lesions during a public-education campaign, but thickness had already been falling before the campaign (Williams 1990, PMID 2390498). Evaluation of the 2016–2022 New South Wales Skin Cancer Prevention Strategy found improved policy awareness, shade access and reported sun-protection behaviour using mixed process and outcome measures, without a melanoma-incidence or mortality endpoint (Mercado 2025, PMID 39663828).
  • The keratinocyte-carcinoma / melanoma boundary is blurred in the general skin-cancer qualitative literature: of 14 studies in the metasynthesis, only three included keratinocyte-carcinoma patients (PMID 27775838), so most of that evidence is melanoma evidence read as skin-cancer evidence.

Interpretation rules for this page

  • Testimonial is not efficacy evidence. Public accounts identify domains of experience, not treatment effects.
  • Report the instrument and its threshold. Fear of recurrence is measured with the FCRI-SF at ≥13 of 36 (PMID 38353983).
  • Carer report and patient report are different data and are kept separate here (PMID 30515757; PMID 39038253).
  • Organisation entries record stated mission and live presence on a dated access, not reach or quality.
  • No private individual is named, quoted or profiled on this page; see ../literature/patient-voice/README.md for the ethics rules applied.

Open questions

  • What intervention reduces fear of recurrence in melanoma survivors, given that the best-designed trial did not (PMID 40504479; PMID 38353983)?
  • How should prognostic uncertainty in the immunotherapy era be communicated when patients and caregivers have conflicting preferences for prognostic information (PMID 39038253)?
  • Can carers be prepared for treatment failure without undermining the hope that sustains them through treatment (PMID 32338133)?
  • What is the patient experience of acral, mucosal and skin-of-colour melanoma, which the qualitative literature has not reached (PMID 27775838; PMID 35533771)?
  • Does personalised genomic risk information change behaviour durably, and does behaviour change reduce melanoma (PMID 30580464; PMID 29558557)?
  • How should prognostic genomic information be delivered in uveal melanoma, where risk is predictable but not modifiable (PMID 41203514; PMID 28810145)?

References

  1. Fu H, et al. Supportive care and unmet needs in patients with melanoma: a mixed-methods systematic review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020;28:3489-3501. PMID 32342223
  2. Mahama AN, et al. Lived Experiences and Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma. JAMA dermatology. 2024;160:495-501. PMID 38353983
  3. Fox JA, et al. Palliative care in the context of immune and targeted therapies: A qualitative study of bereaved carers' experiences in metastatic melanoma. Palliative medicine. 2020;34:1351-1360. PMID 32338133
  4. Fox JA, et al. Uncertain diagnosis and prognosis in advanced melanoma: a qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies. The British journal of dermatology. 2019;180:1368-1376. PMID 30515757
  5. Hansen SM, et al. Employing skin self-examination and fear of cancer recurrence management in early-stage melanoma follow-up: evaluation of the MELACARE intervention in a randomised controlled trial. Journal of cancer survivorship : research and practice. 2025;. PMID 40504479
  6. Bath-Hextall F, et al. The needs and experiences of patients with skin cancer: a qualitative systematic review with metasynthesis. The British journal of dermatology. 2017;177:666-687. PMID 27775838
  7. Lamprell K, et al. When Patients Tell Their Own Stories: A Meta-Narrative Study of Web-Based Personalized Texts of 214 Melanoma Patients' Journeys in Four Countries. Qualitative health research. 2018;28:1564-1583. PMID 29173015
  8. Brown SL, et al. Seven-year distress trajectories in uveal melanoma survivors. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 2023;42:247-256. PMID 36848060
  9. Brown SL, et al. Fear of cancer recurrence and adverse cancer treatment outcomes: predicting 2- to 5-year fear of recurrence from post-treatment symptoms and functional problems in uveal melanoma survivors. Journal of cancer survivorship : research and practice. 2023;17:187-196. PMID 34850324
  10. Müller A, et al. Anxiety, depression and fear of cancer recurrence in uveal melanoma survivors and ophthalmologist/oncologist communication during survivorship in France - protocol of a prospective observational mixed-method study. BMC psychiatry. 2024;24:812. PMID 39548476
  11. Dieng M, et al. Patients' Views About Skin Self-examination After Treatment for Localized Melanoma. JAMA dermatology. 2019;155:914-921. PMID 31090868
  12. Moncrieff MD, et al. Follow-up Schedule for Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial. Annals of surgery. 2022;276:e208-e216. PMID 35866644
  13. Boulanger MC, et al. Patient and Caregiver Experience With the Hope and Prognostic Uncertainty of Immunotherapy: A Qualitative Study. JCO oncology practice. 2025;21:178-187. PMID 39038253
  14. Lleshi K, et al. Impact on Quality of Life and Psychological Dimensions in Caregivers of Melanoma and Sarcoma Patients: A Scoping Review. Cancers. 2026;18. PMID 41827744
  15. Wolchok JD, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2025;392:11-22. PMID 39282897
  16. Moncrieff MD, et al. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Annals of surgical oncology. 2018;25:2541-2549. PMID 29850955
  17. Askew RL, et al. Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2011;14:900-6. PMID 21914512
  18. Swartz RJ, et al. Reducing patient burden to the FACT-Melanoma quality-of-life questionnaire. Melanoma research. 2012;22:158-63. PMID 22395418
  19. Winstanley JB, et al. The FACT-Melanoma quality-of-life instrument: comparison of a five-point and four-point response scale using the Rasch measurement model. Melanoma research. 2013;23:61-9. PMID 23262441
  20. Dieng M, et al. Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma. JAMA dermatology. 2018;154:52-59. PMID 29188268
  21. Reinhardt ME, et al. A systematic review of patient-reported outcome measures for advanced skin cancer patients. Archives of dermatological research. 2023;315:1473-1480. PMID 36469125
  22. Chernyshov PV, et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019;33:816-827. PMID 30963614
  23. Bührer E, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet. Oncology. 2024;25:1202-1212. PMID 39146951
  24. Coens C, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2017;18:393-403. PMID 28162999
  25. Thom B, et al. The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. Journal of psychosocial oncology. 2021;39:285-293. PMID 33103948
  26. Gautron Moura B, et al. Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers. 2022;15. PMID 36612030
  27. Ochenduszko S, et al. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit. Critical reviews in oncology/hematology. 2024;202:104443. PMID 39025250
  28. Fenton GL, et al. Exploring the emotional and behavioural reactions to receiving personalized melanoma genomic risk information: a qualitative study. The British journal of dermatology. 2019;180:1390-1396. PMID 30580464
  29. Müller A, et al. [How do doctors communicate results of genomic testing and its prognostic impact on uveal melanoma patients? Results of a qualitative study]. Bulletin du cancer. 2026;113:165-174. PMID 41203514
  30. Brunsgaard EK, et al. Melanoma in skin of color: Part I. Epidemiology and clinical presentation. Journal of the American Academy of Dermatology. 2023;89:445-456. PMID 35533771
  31. Yan BY, et al. Survival differences in acral lentiginous melanoma according to socioeconomic status and race. Journal of the American Academy of Dermatology. 2022;86:379-386. PMID 34363907
  32. Henrikson NB, et al. Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;319:1143-1157. PMID 29558557
  33. Robertson AG, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer cell. 2017;32:204-220.e15. PMID 28810145
  34. Williams HC, et al. Evaluation of public education campaigns in cutaneous melanoma: the King's College Hospital experience. The British journal of dermatology. 1990;123:85-92. PMID 2390498
  35. Mercado S, et al. Effectiveness of cross-sector collaboration in strategy implementation and impact: Evaluation of the NSW Skin Cancer Prevention Strategy 2016-2022. Health promotion journal of Australia. 2025;36:e934. PMID 39663828